PBMs receive extra “inflation payments” from drug manufacturers to cover annual increases in a drug’s list price. But these payments are not classified as rebates. Similarly, PBMs charge drug companies “administrative fees,” “service fees,” and more for their services. But these fees also aren’t considered rebates. So PBMs don’t pass them along to health plans. They keep them all for themselves.